Search Clinical Trials in the European Union

>2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
1661-1680 of 1,743 trials

Advanced Cancers: Testing IPH4502

We are investigating the safety and effects of a new drug, IPH4502, in people with advanced cancers. This study aims to understand how the drug works in humans for the first time.

Advanced Solid Tumors>2 yearsSafety phase (I)Oncology

Ovarian Cancer: PARP Inhibitor with Cisplatin and Heat Therapy

We are studying a new treatment approach for ovarian cancer that combines a PARP inhibitor with cisplatin and heat during surgery. This trial aims to see if this combination improves outcomes for patients.

Fallopian Tube CancerOvarian CancerExtraovarian Cancer>2 yearsSafety phase (I)Efficacy phase (II)Gynecology and ObstetricsOncology

New T Cell Therapy for Pediatric Blood Cancers

We are testing a modified T cell treatment for children with relapsed or hard-to-treat B-cell leukemia and lymphoma. The study aims to evaluate safety and effectiveness in helping these patients achieve remission.

Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesHematologyOncologyPediatrics

Alzheimer's Disease: MK-2214 Study

We are testing a new medication, MK-2214, in people with early Alzheimer's disease to see if it may slow the progression of brain changes. The study will also evaluate the safety of this treatment compared to a placebo.

Alzheimer's Disease>2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

AL Amyloidosis: Teclistamab Treatment Study

We are investigating whether teclistamab can improve blood health in patients with previously treated AL amyloidosis. This study will also look at the treatment's safety and its effects on quality of life.

Amyloid Light-Chain Amyloidosis>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Chronic Heart Failure: Omecamtiv Mecarbil Study

We are testing a new medication for people with chronic heart failure and severely reduced heart function. The study aims to see if it can improve heart health outcomes compared to a placebo.

Heart Failure with Reduced Ejection Fraction>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atrial Fibrillation: Flecainide vs. Amiodarone

We are studying whether flecainide is more effective and safe than amiodarone for treating paroxysmal atrial fibrillation in patients with coronary disease. This trial aims to see if it can restore normal heart rhythm faster and reduce hospital visits.

Coronary Artery DiseaseParoxysmal Atrial Fibrillation>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCardiologyInternal Medicine

Ketamine for Depression: Brain Imaging Study

We are investigating how different forms of ketamine affect brain function in individuals with depression. This study aims to improve our understanding of how ketamine may help in treating this condition.

Healthy Participants>2 yearsSafety phase (I)Standard MedicinesPsychiatry

Non-Small Cell Lung Cancer: Cemiplimab and TEDOPI® Study

We are testing a new combination therapy for patients with non-small cell lung cancer who have not progressed after initial treatment. The goal is to see if this therapy helps clear cancer markers and improves survival compared to standard treatment.

Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Systemic Lupus Erythematosus: CC-97540 CAR T Cell Therapy

We are studying a new CAR T cell therapy for people with active lupus who haven't responded to standard treatments. The goal is to see if it can improve symptoms and overall health.

Systemic Lupus ErythematosusLupus Nephritis>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyRheumatology

Chronic HDV Infection: Tobevibart and Elebsiran Study

We are studying a new combination therapy for people with chronic HDV infection who haven't responded to prior treatment. The goal is to see if this therapy can effectively reduce the virus and improve liver health.

Chronic Hepatitis D Virus Infection>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHepatologyInfectious Diseases

Cognitive Improvement in Down Syndrome: Bumetanide Study

We are investigating whether Bumetanide can enhance cognitive functions in children and adolescents with Down syndrome aged 10-16. This study aims to explore its effects on both thinking skills and related psychological aspects.

Down Syndrome>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPediatricsPsychiatry

IgA Nephropathy: Felzartamab Infusions

We are studying the effects of felzartamab infusions on adults with IgA nephropathy to see if it helps reduce protein in urine and improve kidney function compared to a placebo.

IgA Nephropathy>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementInternal MedicineNephrology

Personalized Treatment for High-Risk Breast Cancer: PETREMAC Trial

We are studying how personalized therapies can improve outcomes for patients with high-risk breast cancer. The trial looks at treatment responses and aims to enhance surgical options while ensuring safety.

Breast Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesOncology

Type 2 Diabetes: NNC9733-0001 Study

We are researching a new medicine, NNC9733-0001, in healthy individuals and those with type 2 diabetes. The goal is to learn more about its effects and potential benefits.

Healthy ParticipantsType 2 Diabetes>2 yearsSafety phase (I)DiabetologyEndocrinology

Hepatocellular Carcinoma: ALN-BCAT Treatment

We are evaluating a new treatment called ALN-BCAT for patients with liver cancer. The goal is to see how well it works compared to current options.

Advanced or Metastatic Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Prostate Cancer: Androgen Deprivation Therapy and PSMA

We are studying how androgen deprivation therapy affects the expression of a specific protein in metastatic prostate cancer. This research may help us understand treatment responses and disease progression better.

Metastatic Prostate Cancer>2 yearsEfficacy phase (II)No PlaceboStandard MedicinesOncologyUrology

Vaginal Estrogen Treatment: Effects on Blood Clotting

We are studying how local vaginal estrogen affects blood clotting in postmenopausal women. This includes examining its impact on women with a history of blood clots.

Vulvovaginal Atrophy>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesGynecology and ObstetricsInternal Medicine

Multiple Sclerosis: OBE-CEL Treatment Study

We are testing a new treatment for people with refractory progressive forms of multiple sclerosis. The study aims to assess its safety and how well it may work.

Progressive Multiple Sclerosis>2 yearsSafety phase (I)Neurology

Type 1 Diabetes: Deferoxamine for Hypoxia Response

We are studying whether deferoxamine can improve how people with type 1 diabetes react to low oxygen levels. This trial will help us understand its potential benefits in managing diabetes.

Type 1 Diabetes>2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesEndocrinologyInternal Medicine